ConductScience.org, home

Paper39883227

Natural compounds as modulators of miRNAs: a new frontier in bladder cancer treatment.

Abulsoud AI and 12 others. Med Oncol, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Natural compounds as modulators of miRNAs: a new frontier in bladder cancer treatment. Papers, record 39883227. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39883227

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Natural compounds as modulators of miRNAs: a new frontier in bladder cancer treatment.
PubMed
Journal
Med Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.89, provisional
iCite
Revised in PubMed
2026-11-01
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Abulsoud AIAhmed I
2Aly SHShaza H
3Abdel Mageed SSSherif S
4Abdelmaksoud NMNourhan M
5El-Dakroury WAWalaa A
6Mohammed OAOsama A
7Abdel-Reheim MAMustafa Ahmedhttps://orcid.org/0000-0002-7728-0923
8Zaki MBMohamed Bakr
9Rizk NINehal I
10El Tabaa MMManar Mohammed
11Rashed MMahmoud
12El-Shiekh RARiham A
13Doghish ASAhmed Shttps://orcid.org/0000-0002-0136-7096

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MicroRNAsMajor topic
Urinary Bladder NeoplasmsMajor topic
Biological ProductsMajor topic
Humans
Animals
Gene Expression Regulation, Neoplastic

References105

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138707615Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs.Drug Des Devel Ther2024https://conductscience.org/library/papers/38707615PubMed
225533674Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Nat Rev Cancer2015https://conductscience.org/library/papers/25533674PubMed
335778656miR-1307-5p suppresses proliferation and tumorigenesis of bladder cancer via targeting MDM4 and the Hippo signaling pathway.Discov Oncol2022https://conductscience.org/library/papers/35778656PubMed
425469061Prevalence and risk factors for depression in Korean adult patients with asthma: is there a difference between elderly and non-elderly patients?J Korean Med Sci2014https://conductscience.org/library/papers/25469061PubMed
538563878Unveiling the pharmacological potential of plant triterpenoids in breast cancer management: an updated review.Naunyn Schmiedebergs Arch Pharmacol2024https://conductscience.org/library/papers/38563878PubMed
619519535Ras-MAPK pathway as a therapeutic target in cancer--emphasis on bladder cancer.Recent Pat Anticancer Drug Discov2009https://conductscience.org/library/papers/19519535PubMed
724490857Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid-induced apoptosis through down-regulation of EZH2 expression by miR-101.Br J Pharmacol2014https://conductscience.org/library/papers/24490857PubMed
834800653Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.Crit Rev Oncol Hematol2021https://conductscience.org/library/papers/34800653PubMed
921836020Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer.Cancer Prev Res (Phila)2011https://conductscience.org/library/papers/21836020PubMed
1023159064Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells.J Nutr Biochem2013https://conductscience.org/library/papers/23159064PubMed
1139003425Natural compounds-based nanomedicines for cancer treatment: Future directions and challenges.Drug Deliv Transl Res2024https://conductscience.org/library/papers/39003425PubMed
1226660324Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?J Cancer Res Clin Oncol2016https://conductscience.org/library/papers/26660324PubMed
1330070321MiR-183 maintains canonical Wnt signaling activity and regulates growth and apoptosis in bladder cancer via targeting AXIN2.Eur Rev Med Pharmacol Sci2018https://conductscience.org/library/papers/30070321PubMed
1439022680Plant bioactive compounds driven microRNAs (miRNAs): A potential source and novel strategy targeting gene and cancer therapeutics.Noncoding RNA Res2024https://conductscience.org/library/papers/39022680PubMed
1531878082Quercetin, Epigallocatechin Gallate, Curcumin, and Resveratrol: From Dietary Sources to Human MicroRNA Modulation.Molecules2019https://conductscience.org/library/papers/31878082PubMed
1628069380microRNA-495 promotes bladder cancer cell growth and invasion by targeting phosphatase and tensin homolog.Biochem Biophys Res Commun2017https://conductscience.org/library/papers/28069380PubMed
1738105263Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.Signal Transduct Target Ther2023https://conductscience.org/library/papers/38105263PubMed
1831612063MicroRNA-34a inhibits bladder cancer cell migration and invasion, and upregulates PTEN expression.Oncol Lett2019https://conductscience.org/library/papers/31612063PubMed
1930412716Long non-coding RNA HOXA-AS2 promotes the migration, invasion and stemness of bladder cancer via regulating miR-125b/Smad2 axis.Exp Cell Res2019https://conductscience.org/library/papers/30412716PubMed
2030149755Curcumin Suppresses microRNA-7641-Mediated Regulation of p16 Expression in Bladder Cancer.Am J Chin Med2018https://conductscience.org/library/papers/30149755PubMed

See all 105 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
41682926Intersection of Precision Nutrition and Bladder Cancer: A Narrative State-of-the-Art Review of Potential Applications and Challenges.J Clin Med2026https://conductscience.org/library/papers/41682926PubMed
41668793Harnessing natural compounds and nanotechnology for miRNA-based osteosarcoma therapy.RSC Adv2026https://conductscience.org/library/papers/41668793PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39883227

GET https://conductscience.org/api/papers/v1/39883227/references?page=2